SIRT6: A potential therapeutic target for diabetic cardiomyopathy

FASEB J. 2023 Aug;37(8):e23099. doi: 10.1096/fj.202301012R.

Abstract

The abnormal lipid metabolism in diabetic cardiomyopathy can cause myocardial mitochondrial dysfunction, lipotoxicity, abnormal death of myocardial cells, and myocardial remodeling. Mitochondrial homeostasis and normal lipid metabolism can effectively slow down the development of diabetic cardiomyopathy. Recent studies have shown that SIRT6 may play an important role in the pathological changes of diabetic cardiomyopathy such as myocardial cell death, myocardial hypertrophy, and myocardial fibrosis by regulating mitochondrial oxidative stress and glucose and lipid metabolism. Therefore, understanding the function of SIRT6 and its role in the pathogenesis of diabetic cardiomyopathy is of great significance for exploring and developing new targets and drugs for the treatment of diabetic cardiomyopathy. This article reviews the latest findings of SIRT6 in the pathogenesis of diabetic cardiomyopathy, focusing on the regulation of mitochondria and lipid metabolism by SIRT6 to explore potential clinical treatments.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diabetes Mellitus* / metabolism
  • Diabetic Cardiomyopathies* / metabolism
  • Humans
  • Mitochondria / metabolism
  • Myocardium / metabolism
  • Myocytes, Cardiac / metabolism
  • Sirtuins* / metabolism

Substances

  • Sirtuins
  • SIRT6 protein, human